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Aim: To compare the efficacy and safety of stent insertion alone to stent insertion combined with any
active oncological treatment in the palliative care of esophageal cancer.
Methods: A meta-analysis and systematic review were performed according to the PRISMA Statement.
Comparative studies with patients receiving stent insertion alone (control group) were compared to
patients receiving oncological therapy in addition to stent placement (intervention group). For mean dys-
phagia grade before stenting, weighted mean differences (WMD), for the complications of stenting, risk
ratios (RR) were calculated, both were interpreted with 95% confidence intervals (CI). Whenever possible,
subgroup analyses were performed for studies with irradiation stents as intervention. Survival, late dys-
phagia, esophageal perforation and medical costs were analyzed via systematic review. The protocol of
the study was registered prior on PROSPERO.
Results: 17 studies with 1177 esophageal cancer patients were included in the final analysis, with 629
and 548 in the control and intervention groups, respectively. We found no significant difference in any
complications of stenting between the two groups. 13 studies reported mean or median survival, and
8 found that combined therapy resulted in a significantly longer life expectancy. In the other 5 studies,
there was no difference in survival between the two groups. Furthermore, additional treatment may
be more effective in the long-term relief of dysphagia than stenting alone.
Conclusions: Irradiation stents may prolong survival, and stenting combined with oncological treatment
does not increase the risk of complications as compared to stenting alone. However, further studies are
warranted.
Core tip: Esophageal cancer is the eighth most common type of malignancy worldwide, and its prognosis
is very poor. This suggests that palliative treatment modalities are paramount in its treatment. Self-
expanding metal stents play an important role in the management of dysphagia caused by the tumor.
However, it is unclear whether any additional oncological therapy should be administered to patients
besides stenting. In this meta-analysis and systematic review, we evaluated the safety and efficacy of
additional oncological therapies alongside stenting versus stenting alone in case of unresectable esopha-
geal cancer.
 2020 Published by Elsevier B.V. Radiotherapy and Oncology 147 (2020) 169–177Esophageal cancer is the eighth most common cancer world-
wide with an estimated annual incidence and mortality above
572,000 and 508,000, respectively [1]. This makes it the sixth lead-
ing cause for cancer-related mortality [2]. Its five-year survival rate
is estimated to be as low as 14% [3] and patients with metastaticdisease have a median survival of less than one year if treated with
chemotherapy [4].
Low survival rates are also explained by the fact that the major-
ity of tumors are unresectable at the time of diagnosis [3]. In most
cases the diagnosis is made after the onset of dysphagia, which
indicates at least locally advanced cancer [5]. The most common
symptom is dysphagia in 74% of patients at the time of diagnosis
[6]. Absence of early symptoms and the lack of precancerous states
make screening procedures difficult to organize effectively [3],
170 Palliation via stenting in unresectable esophageal cancerwith the exception of Barrett’s esophagus, where surveillance is
recommended [7].
Such high mortality rates underline the importance of palliative
treatment options. Endoscopic stenting with metal stents plays an
important role in the management of malignant dysphagia to
achieve immediate dysphagia relief and quality of life improve-
ment [8].
Currently, there are no clear guidelines on whether additional
oncological treatment is required besides stenting in the palliative
care of esophageal cancers [9]. Stenting may be combined with
various types on oncological treatment, including photodynamic
therapy, brachytherapy (irradiation stents), radiotherapy,
chemotherapy, or chemo-radiotherapy. At present, the decision
lies in the hands of individual clinicians, and is usually based on
patient characteristics, such as performance status, presence of
metastases, age and expected survival time [9].
Our study aims to quantitatively and qualitatively analyze the
potential benefits, drawbacks and safety measures of oncological
treatment administered in addition to palliative stenting for incur-
able esophageal cancer.
Methods
We conducted a meta-analysis and systematic review following
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement [10]. Our work was performed in
accordance with the Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [11]. The protocol was registered
in PROSPERO under registration number CRD42018093921 [12].Search
Two independent authors (BT and LS) carried out a comprehen-
sive search using six electronic databases (PubMed, EMBASE, the
Cochrane Library, Web of Science, clinicaltrials.gov, and the WHO
Global Health Library) with the purpose of gathering all relevant
articles on the topic of palliative stent therapy in esophageal cancer
patients from inception until 10 February 2020.
Our PICO items were as follows: we looked for studies on
patients with incurable esophageal cancer (P) that compare two
palliative treatment modalities: stent insertion alongside any addi-
tional active oncological therapy (I) or stent insertion alone (C). The
primary outcomes were mean survival time after stent insertion
and the relief of dysphagia. Secondary outcomes were the compli-
cations of stenting (such as hemorrhage, deaths due to hemor-
rhage, chest pain requiring opiate analgesics, fever, stent
migration, restenosis or obstruction, tracheoesophageal fistula for-
mation, aspirational pneumonia and esophageal perforation) and
the cost of the medical treatment (O).
The query ‘‘(esophagus OR oesophagus) AND ((malignan* OR
cancer* OR carcinoma) AND (stricture OR stenosis OR obstruction
OR blockage OR dysphagia)) AND (stent OR onco* OR radio* OR
chemo* OR beam OR best supportive OR palliat*)” was used in all
six databases. For a draft of our search strategy, see Supplementary
1.
The ‘‘human” filter was applied when searching in PubMed,
EMBASE and the WHO Global Health Library. The ‘‘trials” and
‘‘completed” filters were used in case of the Cochrane Library
and clincaltrials.gov, respectively. We imposed no language
restriction to our search.Inclusion and exclusion criteria
We included both observational and interventional studies
except for case studies, case reports, editorials, comments, letters
and reviews. Conference abstracts were included if they containedsufficient data for analysis. We included studies with either
prospective or retrospective data collection, regardless of their pri-
mary objectives. In case of multiple publications on the same group
of patients, the most recent record was chosen.
The inclusion criteria required patients to be over 18 years of
age, with a diagnosis of incurable, late-stage esophageal cancer
(of any histological subtype). An intervention and a control group
both had to be present in the same study in order to provide com-
parability. The control group was defined as patients receiving any
type of metallic stent implantation for palliative purposes, without
the concurrent addition of other active treatment modality. The
indication for stenting was malignant dysphagia. The intervention
group consisted of those patients who received a metallic esopha-
geal stent of any kind in combination with any type of active
oncotherapy (radio-, chemo-, or photodynamic therapy) for pallia-
tive purposes. Insertion of irradiation stents was considered an
intervention, as brachytherapy delivered by the stent is an addi-
tional active oncological treatment modality.Screening and selection
Articles yielded by the initial search were imported into a refer-
ence management program (EndNote X7, Clarivate Analytics,
Philadelphia, PA, USA). The same software was utilized for the
removal of duplicates by searching for articles with overlapping
publication year, authors or title.
After duplicate removal, two independent researchers (BT and
LS) simultaneously screened all remaining articles against the
pre-defined eligibility criteria first by title, abstract and then full
text in order to find studies for inclusion. Reference lists of selected
articles were searched to identify studies potentially missed by the
electronic search. Any disagreements were resolved by arbitration
by a third investigator (BE).Data extraction
Two investigators separately extracted data from studies
included and manually entered them on a Microsoft Excel 2016
sheet (Office 365, Microsoft, Redmond, WA, USA). Data were col-
lected on first author, publication year, study type, geographical
location, definition of control and intervention groups, demograph-
ical characteristics of patients included, and histological subtype of
the tumors. Finally, data were collected on the aforementioned
outcomes of interest. Differences in the data sheets were resolved
by consensus.Quality assessment and quality of evidence
We used a modified version of the Newcastle-Ottawa Scale
(NOS) for the quality assessment of cohort studies included in
our analysis [13]. Supplementary 2 shows the NOS Quality Assess-
ment Form for Cohort Studies modified to fit the study design of
the articles included. The Cochrane Risk of Bias Tool was used to
assess the quality of the randomized-controlled trials [14]. The
Grading of Recommendations Assessment, Development and Eval-
uation (GRADE) methodology was used to rate the quality of evi-
dence as high (level A), moderate (level B), low (level C) or very
low (level D) [15].Data synthesis and analysis
In case of the survival time and the dysphagia grade weighted
mean differences (WMD) were calculated with their 95% confi-
dence intervals (CI). In other comparisons, risk ratios (RRs) with
95% CI were calculated from the raw data extracted. Subgroup
analyses were also performed by treatment type. Pooled estimates
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Laird method [16]. Results of the meta-analysis were displayed
graphically using forest plots. Heterogeneity was tested by using
the Cochrane’s Q and the I2 statistics, where I2 = 100%  (Q  df)/
Q, and represents the magnitude of the heterogeneity (moderate:
30–60%, substantial: 50–90%, considerable: 75–100%) [11]. All
meta-analytical calculations were performed by Stata v15.1 soft-
ware (Stata Corp LLC, College Station, TX, USA).Results
Our search yielded a total of 14,960 articles, 1226 in PubMed,
9505 in EMBASE, 355 in the Cochrane Library, 1503 in Web of
Science, 2371 in the WHO Global Health Library, and 0 in clinical-
trials.gov. Four articles were identified by cross-referencing. After
duplicate removal and three-step selection, a total of 40 articles
were assessed for eligibility by their full text. Out of these studies,
23 were excluded for the following reasons: lack of intervention
group (6 studies, [17–22]), lack of a control group (3 studies,
[23–25]), insufficient outcome data (7 studies, [26–32]), use of
non-metallic stents (2 studies, [33,34]), patients with curable can-
cer (2 studies, [35,36]) and curative intent (3 studies, [37–39]). For
a summary of our search and selection, see Fig. 1: PRISMA flow-
chart of the study selection process.
Finally, 17 studies were deemed eligible for either qualitative or
quantitative synthesis [40–56]. These included a total of 1177 sub-
jects, out of which 629 and 548 patients received stent therapy
alone (control group) or stent therapy supplemented by additional
oncological treatment (intervention group), respectively. In case of
234 patients, brachytherapy with I125-coated irradiation stents was
the intervention method of choice, which provided basis for
subgroup-analysis. Characteristics of studies included are shown
in Table 1.
Tables 2 and 3 contain data collected on outcomes included in
the meta-analysis, and Table 4 shows a summary of the results
of the quantitative synthesis.Fig. 1. PRISMA flowchart for the study selection process.Complications of stenting. We found no significant association
between additional oncological treatment and complications of
the stenting procedure, such as chest pain requiring opiate anal-
gesics (RR, 1.03; 95% CI, 0.84–1.26; I2 0.0%; Supplementary 3),
hemorrhage (RR, 1.32; 95% CI, 0.89–1.98; I2 0.0%; Supplementary
4) and deaths due to hemorrhage (RR, 1.19; 95% CI, 0.67–2.11; I2
0.0%; Supplementary 5). Neither increased risk of stent migration
(RR, 0.96; 95% CI, 0.51–1.78; I2 0.0%; Supplementary 6), nor stent
restenosis or obstruction (RR, 0.62; 95% CI, 0.36–1.09; I2 21.6%;
Supplementary 7) were associated with additional treatment. Fis-
tula formation and development of aspirational pneumonia and
development of fever as complications of stenting also did not
show association with additional active oncotherapy (RR, 1.62;
95% CI, 0.68–3.87; I2 0.0%; RR, 0.76; 95% CI, 0.40–1.45; I2 0.0%;
RR, 1.24; 95% CI, 0.61–2.50; I2 0.0%; Supplementary 8–10,
respectively).
Subgroup-analyses of studies where irradiation stents were
used [40,42,44,45,48,54,55] as intervention were performed when-
ever possible, showing no association with any of the complica-
tions examined (see Supplementary 3, 4, 6, 7, 8).
Dysphagia score before stenting and within 3 days of stenting. We
found no significant difference between the two groups in dyspha-
gia scores prior to and within 3 days of the stenting procedure
(WMD, 0.03; 95% CI, 0.11–0.05; I2 0.0%; WMD, 0.08; 95% CI,
0.01–0.17; I2 0.0%; see Supplementary 11 and 12, respectively).
Table 5 demonstrates data extracted on outcomes analyzed in
the systematic review section of our study.
Survival after stenting. 13 studies reported this outcome as mean
or median survival time after stent insertion [40–46,48–51,54,55].
Out of the 13 articles, 12 compared the survival of patients in the
two groups via log rank test [40–45,48–51,54,55]. These 12 articles
included a total of 894 patients, out of which 473 and 421 belonged
to the control and intervention group, respectively. The use of
additional oncological treatment was associated with prolonged
survival in 8 of these 12 studies [40,41,43,45,48,49,54,55] compar-
ing a total of 542 patients, with 281 in the control group and 261 in
the intervention group, respectively. The remaining 4 studies (352
total patients; 212 and 140 patients in the control and intervention
group) found no significant difference between survival in the two
groups [[42,44,50,51]]. No study showed significantly reduced sur-
vival time in patients that received stenting and additional onco-
logical therapy as compared to stenting alone.
Regarding the sub-group of 7 articles (539 total patients, 254
and 285 patients in the control and intervention groups) where
iodine-coated stents were used as intervention
[40,42,44,45,48,54,55], 5 (345 total patients; 182 versus 163
patients in the control and intervention group) reported that that
irradiation stents significantly prolong survival as compared to
regular stents [40,45,48,54,55]. At the same time, 2 articles (194
patients, 72 in the control and 122 in the intervention group) found
no significant difference between the two groups [42,44]. No arti-
cles suggested that irradiation stents are associated with reduced
survival as compared to regular stents. Detailed results of this out-
come in each study can be found in Table 6.
Late dysphagia. The studies contained insufficient data on dys-
phagia scores more than 3 days after the stenting procedure, there-
fore only quantitative synthesis was carried out in case of this
outcome. 5 studies [40,42,48,49,57] of the included 17 contained
data on the long-term improvement of dysphagia. Guo et al. found
that dysphagia was equally well palliated in both groups up until
the second month after treatment, where the intervention group
had a significantly lower dysphagia score (exact dysphagia score
values were not specified in the article, p < 0.05) [40]. Liu et al. con-
cluded that there was no significant difference between dysphagia
scores of patients in the control and intervention groups at 1 month
after stenting (mean dysphagia score at 1 month 1.6 and 1.7 in the
Table 1
Characteristics of studies included.
Author
(publication
year)
Country Design Group definitions (C: Control; I:
Intervention)
Patient
Number (n)
Male
(n)
Age (years,
mean, SD)
Follow-up
(months, mean)
Histology
AC/SCC (n)
Bakheet (2019) South
Korea
Retrospective
cohort
C: SEMS alone 41 38 67.7(11)
I: SEMS + chemotherapy 64 60 66.7(10.7)
Tian (2016) China Cohort C: SEMS alone 91 67 66.3 (9.4) 4 (median) 0/90
I: I125-coated Irradiation stent 40 30 66.9 (8.6) 4 (median) 0/41
Zhao (2016) China RCT C: SEMS alone 25 0/25
I: I125-coated Irradiation stent 18 0/18
Kim (2015) South
Korea
Retrospective
cohort
C: SEMS alone 45 7/10
I: SEMS + multiple modalities of
oncological treatment
44 3/9
Liu (2014) China Cohort C: Conventional SEMS 32 20 61.2 2.7 5/27
I: I125-coated Irradiation stent 31 16 59.6 3.4 6/25
Zhu (2014) China RCT C: SEMS alone 75 53 71(median) 4.1(median) 14/61
I: I125-coated irradiation stent 73 61 71(median) 5.7(median) 8/65
Zhongmin
(2012)
China Cohort C: Covered stent alone 30 18 68.8(6.9) 12/18
I: I125-coated Irradiation stent 28 19 65(7.9) 8/20
Xu (2011) China RCT C: SEMS alone 17
I: I125-coated Irradiation stent 15
Zhao (2011) China Cohort C: SEMS alone I: I125-coated Irradiation
stent
25
18
Burstow (2009) Australia Retrospective
cohort
C: SEMS alone I: Adjuvant chemotherapy,
radiotherapy, or both
67
23
Guo (2008) China RCT C: Conventional covered stent 27 20 69.54 (8.68) 3.3 6/20
I: I125-coated irradiation stent 26 19 72.19 (8.71) 7.2 5/22
Zhang (2005) China Cohort C: Metal stent only 34 25 62.04 2/31
I: Endoprothesis and external
radiotherapy
33 26 60.17 2/30
Fu (2004) China RCT C: SEMS alone 27 16 64.2 (14) 2/23
I: Stent + external radiotherapy and/or
chemotherapy
26 23 59.4 (9.6) 2/24
Javed (2004) India RCT C: SEMS alone 37 27 58.1 (12.44) 6/31
I: Stent + external beam radiotherapy 42 29 58.6 (12.13) 7/35
Zhong (2003) China Cohort C: SEMS alone 18 13 64.6 0/18
I: SEMS + external radiotherapy and/or
chemotherapy
16 12 61.5 0/16
Ludwig (1998) Germany Cohort C: Nitinol stent or wallstent 17 13 67 (median) 7/10
I: stent combined with
radiochemotherapy
12 11 57 (median) 3/9
Raijman (1997) USA Retrospective
cohort
C: Coated expandable wallstent alone 21 10 66.8 6.4 8/13
I: Stent + chemo/radio/both 39 29 64.7 5.9 12/14
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however, the difference between the two groups became signifi-
cant (mean dysphagia scores 2.6 vs 2.1 in the control and interven-
tion groups, respectively, p = 0.03) [42]. In case of the article by Zhu
et al., dysphagia was significantly lower in the intervention group
as compared to the control group starting from 1 month after the
procedure to the end of the follow-up [48]. Javed et al. states that
the mean dysphagia score was comparable between the two
groups up until 3 months post-treatment. Thereafter, dysphagia
scores at 5 and 7 months were significantly lower in the interven-
tion group [49]. Zhong et al. found that stenting dramatically
improved dysphagia of patients, however patients in the control
group had an increasing tendency of dysphagia grades 9 months
after stent implantation (mean dysphagia in the control and inter-
vention groups at 9 months after stenting; 1.75(±0.35) 4 and 1.58
(±38) respectively; statistical analysis not reported).
Perforation. 5 studies [42,45,47,49,53] on a total of 312 patients
included data concerning esophageal perforation (or a lack thereof)
as a complication of stenting. Perforation only occurred in two
studies [42,53], with a combined rate of 6.1% (4/66) and 9.4%
(6/64) in the control and intervention group, respectively. Out of
the total 182 patients (83 in the control group and 99 in the inter-
vention group) of the other 3 studies [45,47,49], no perforation was
observed. None of the articles found a significant difference
between the two groups (p = 0.672 in case Liu et al.).Medical costs. Only one article out of 17 [44] assessed medical
costs as an outcome. They reported that regular stent treatment
received by the control group to be significantly cheaper than
treatment with irradiation stent in the intervention group (7000
and 26,000 Chinese yuan, approximately 1000 and 3800 USD
respectively, p < 0.01) [44].
Supplementary 16 and 17 represent the results of the quality
assessment of the studies included.
Applying the GRADE approach to each of the outcomes assessed
above resulted in a very low (D) level of evidence for every
outcome.Discussion
It is established knowledge that self-expanding metal stent
insertion provides an acute relief of malignant dysphagia with an
immediate success rate of 90–100% [57,58]. At the same time,
recurring dysphagia within 4 to 10 weeks after stenting occurs in
around 50% of patients [38,59]. On the other hand, radiotherapy
exceeds at relieving long-term dysphagia [60], but the onset of
its beneficial effects is slow, and may even worsen dysphagia early
on due to radiation-induced swelling [49].
A randomized-controlled trial in 2005 demonstrated longer
ongoing dysphagia relief with radiotherapy than stent alone [37].
Table 2
Data extracted on outcomes synthetized via meta-analysis, part 1.
Author (year of
publication)
Group (C: control; I:
intervention)
Patient
Number (n)
Severe chest
pain (n)
Hemorrhage
(n)
Deaths due to
hemorrhage (n)
Stent
migration (n)
Restenosis/stent
obstruction (n)
Bakheet (2019) C 41 2
I 64 8
Tian (2016) C 91 16 6 6 5 4
I 40 12 1 1 2 2
Zhao (2016) C 25 3 0 0 0 3
I 18 2 0 0 0 2
Kim (2015) C 45
I 44
Liu (2014) C 32 9 7 3 4
I 31 8 11 4 3
Zhu (2014) C 75 15 5 5 0
I 73 17 5 6 0
Zhongmin (2012) C 30 24 2 2
I 28 15 1 1
Xu (2011) C 17 4 4 7
I 15 3 4 3
Zhao (2011) C 25 4 0 0
I 18 3 0 0
Burstow (2009) C 67
I 23
Guo (2008) C 27 7 7 7 3 6
I 26 8 9 9 2 8
Zhang (2005) C 34 3 3 7
I 33 7 2 1
Fu (2004) C 27 4 1 9
I 26 7 2 1
Javed (2004) C 37 0 9
I 42 1 6
Zhong (2003) C 18 1 2 1
I 16 0 3 0
Ludwig (1998) C 17
I 12
Raijman (1997) C 21 4 2
I 39 9 2
Table 3
Data extracted on outcomes synthetized via meta-analysis, part 2.
Author (year of
publication)
Group (C: control; I:
intervention)
Patient
Number (n)
Mean dysphagia grade
before stentinga
Mean dysphagia grade within
3 days of stentinga
Fistula
formation (n)
Aspirational
pneumonia (n)
Bakheet (2019) C 41 3.15 1.17
I 64 3.17 1.14
Tian (2016) C 91 3.27 0.20
I 40 3.28 0.38
Zhao (2016) C 25
I 18
Kim (2015) C 45
I 44
Liu (2014) C 32 3.03 1 3
I 31 3.10 2 2
Zhu (2014) C 75 3.40 1.30 5 14
I 73 3.30 1.40 6 11
Zhongmin (2012) C 30 3.40
I 28 3.43
Xu (2011) C 17
I 15
Zhao (2011) C 25
I 18
Burstow (2009) C 67
I 23
Guo (2008) C 27 3.12 1.04 0 2
I 26 3.22 1.07 1 1
Zhang (2005) C 34 2.15 1
I 33 2.18 3
Fu (2004) C 27
I 26
Javed (2004) C 37 3.22 0
I 42 3.10 0
Zhong (2003) C 18 3.11
I 16 3.06
Ludwig (1998) C 17
I 12
Raijman (1997) C 21 3.60 1.40
I 39 3.50 1.40
a Measured on a 4-grade scale.
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Table 4
Results of the meta-analysis.
N of studies RR or WMD (95% CI) I2 (%)
Chest pain requiring opioids
All studiesa 12 1.03 (0.84–1.26) 0.0
Irradiation stent only 8 0.96 (0.84–1.26) 5.2
Other oncological treatment 4 1.03 (0.63–4.21) 0.0
Hemorrhage
All studiesa 11 1.32 (0.89–1.98) 0.0
Irradiation stent only 7 1.25 (0.79–1.97) 0.0
Other oncological treatment 4 1.62 (0.71–3.71) 0.0
Deaths due to hemorrhage
Irradiation stent onlyc 5 1.19 (0.67–2.11) 0.0
Stent migration
All studiesa 11 0.96 (0.51–1.78) 0.0
Irradiation stent only 7 0.78 (0.35–1.71) 0.0
Other oncological treatment 4 1.34 (0.49–3.68) 0.0
Stent restenosis
All studiesa 8 0.62 (0.36–1.09) 21.6
Irradiation stent only 5 0.92 (0.51–1.66) 0.0
Other oncological treatment 3 0.29 (0.09–0.93) 39.7
Fistula formation
All studiesa 5 1.62 (0.68–3.87) 0.0
Irradiation stent only 3 1.47 (0.55–3.91) 0.0
Other oncological treatment 2 2.35 (0.34–16.10) 0.0
Aspirational pneumonia
All studiesa 3 0.76 (0.40–1.45) 0.0
Fever
All studiesa 3 1.24 (0.61–2.50) 0.0
Dysphagia grade before stenting
All studiesa 7 0.03b (-0.11–0.05) 0.0
Dysphagia grade after stenting within 3 days
All studiesa 4 0.08b (-0.01–0.17) 0.0
OR: odds ratio; WMD: weighted mean difference.
a All studies where the corresponding outcome was reported.
b Weighted mean difference.
c Only studies with irradiation stents contained this outcome.
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insertion and the long term effect of brachytherapy make the com-
bination of palliative stenting and radiotherapy a rational decision.
Several individual studies suggest that brachytherapy using irradi-
ation stents is associated with prolonged survival, in addition to
the effective treatment of dysphagia (both acutely and on the
long-term) [56,61].
Our meta-analysis did not find a significant difference in any
assessed complications of stenting between the two groups, which
suggests that active oncological therapy combined with stenting is
non-inferior to stenting alone in terms of its safety. Our analysis
did not cover the potential differences in quality of life between
the two groups; however we believe this to be an important
parameter to monitor, which should be taken into consideration
when designing future trials.Limitations and explanation of heterogeneity
While conducting the meta-analysis, we came across several
limitations that may potentially impair the strength of our
findings.
Regarding differences in patient populations, the tumor stage of
involved patients varied from study to study. The articles reported
this characteristic inconsistently, by describing the mean tumor
stage [44,48,50], the number of patients with metastatic cancer
[40,42,49,50], or the ECOG performance scale of the patients [48].
Methodological differences between studies include that the
modality of active oncological treatment was not the same in every
article. Most studies utilized I125-coated irradiation stents in theintervention group [40,42,44,45,48,54,55]. In other cases, external
radiotherapy, chemotherapy or both were applied in addition to
stenting as intervention [41,43,46,47,49,50].
Statistical methods did not reveal the causes for heterogeneity
among the included studies. The major confounding factors
accounting for the heterogeneity are likely the differences between
the populations (age, gender ratio, histological type of cancer) in
the individual studies, the differences between the standard of pal-
liative care. Chronological bias may be another important con-
founder as studies spread between 1997 and 2019.
Another methodological difference is the inconsistency of
follow-up periods. Only 5 studies out of the analyzed 17 included
data on the follow-up time of patients [40,42,44,47,48].
In case of two articles, patients were allowed to receive differ-
ent treatment in addition to the treatment modalities of their
assigned group. In Zhao et al., the use of alternative medicine
and chemotherapy was allowed before, concurrently with, or after
the assigned treatment [45]. In the study conducted by Guo et al.,
some patients received traditional Chinese medicine as well as
their assigned treatment [40].
With regards to the outcomes assessed, we found slight differ-
ences in the definition of dysphagia between studies. Although
every article that assessed dysphagia did so as a 0–4 scale, the def-
inition of each value varied slightly.
Generalizability of the findings is questionable as the majority
of studies are from China, some, from the same center, with squa-
mous cell cancer as the predominant type of esophageal cancer. As
environmental and genetic factors may be very different, the
results above may not be reproducible in Western populations.
Table 5
Data extracted on outcomes synthetized via systematic review ameasured on a 4-grade scale, bmeasure of effect not specified in the article.
Author (year
of
publication)
Group (C:
control; I:
intervention)
Patient
Number
(n)
Mean dysphagia grade
after stenting at 1
montha
Mean dysphagia grade
after stenting at 3
monthsa
Mean dysphagia grade
after stenting at 5
monthsa
Fever
(n)
Medical costsb
(Chinese
yuan)
Perforation
(n)
Bakheet
(2019)
C 41
I 64
Tian (2016) C 40 7000
I 91 26,000
Zhao (2016) C 25 0
I 18 0
Kim (2015) C 45
I 44
Liu (2014) C 32 1.60 2.60 4 3
I 31 1.70 2.10 6 2
Zhu (2014) C 75 1.76 2.56 2.65
I 73 1.74 1.85 1.87
Zhongmin
(2012)
C 30
I 28
Xu (2011) C 17 5
I 15 6
Zhao (2011) C 25
I 18
Burstow
(2009)
C 67
I 23
Guo (2008) C 27 1.17 3
I 26 1.22 1
Zhang (2005) C 34 1
I 33 4
Fu (2004) C 27
I 26
Javed (2004) C 37 1.27 2.55 0
I 42 1.27 1.45 0
Zhong (2003) C 18 1.36
I 16 1.29
Ludwig
(1998)
C 17
I 12
Raijman
(1997)
C 21 0
I 39 0
B. Tinusz et al. / Radiotherapy and Oncology 147 (2020) 169–177 175Our meta-analysis found that stenting with additional active
oncological therapy does not increase the risk for complications
of stenting in case of patients diagnosed with unresectable esopha-
geal cancer as compared to stenting alone. Furthermore, our sys-
tematic review strongly suggests that additional oncological
therapy may prolong the survival of patients after stenting, and
irradiation stents may be more effective in the relief of late dys-
phagia when compared to stenting alone.
However, due to the differences in study design, definition of
outcomes and patient characteristics of the studies included, the
quality of evidence remains very low. We believe that further
large-scale, randomized-controlled trials are warranted to assess
the effectiveness and safety of palliative treatment modalities in
esophageal cancer.
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Author (year of
publication)
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Intervention)
Patient number
(n)
Survival time
(months)
p value of the long-rank
test
Bakheet (2019) Retrospective
cohort
C 41 4.41 (3.23–5.57)3 0.592
I 64 5.21 (4.4–6.0)3
Tian (2016) Cohort C 40 4.21 (2.8)4 0.752
I 91 4.41 (2.4)4
Zhao (2016) RCT C 25 4.81 (3.9)4 <0.01
I 18 9.81 (4.3)4
Kim (2015) Retrospective
cohort
C 45 3,21 (3.0)4 <0.001
I 44 5,61 (4.2)4
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Fu (2004) RCT C 27 8.171 (5.47–10.83)3 0.813
I 26 8.731 (6.97–11.5)3
Javed (2004) RCT C 37 42 0.009
I 42 62
Ludwig (1998) Cohort C 17 4.62 (0.85–25.7)5 <0.05
I 12 8.02 (0.3–10.57)5
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